Literature DB >> 15131537

Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation.

Azfar G Zaman1, Mark T Kearney, Clyde Schecter, Stephen G Worthley, James Nolan.   

Abstract

OBJECTIVES: The purpose of the current study was to assess the effect of angiotensin-converting enzyme inhibitor (ACEI) therapy in facilitating cardioversion from persistent atrial fibrillation (AF) and maintaining sinus rhythm.
BACKGROUND: Pharmacologic therapy and electrical cardioversion for AF are often unsuccessful in maintaining long-term sinus rhythm.
METHODS: The current study, a 1-year, prospective follow-up, comprised 47 patients with persistent AF undergoing electrical cardioversion. Patients receiving ACEI were compared with those receiving other medications. The study end point was the number of defibrillation attempts required for atrial defibrillation and the number of hospital admissions. A secondary end point was change in signal-averaged P-wave duration (SAPD) 1 year after successful electrical cardioversion.
RESULTS: Of those admitted and requiring electrical defibrillation, the number of defibrillation attempts required for successful cardioversion was significantly less in the ACEI group (P <.001). The incidence rate ratio for admissions comparing recipients of ACEI with others was 0.14 (P =.03). Patients receiving ACEI therapy had significantly lower SAPD at 1 year when compared with the no-ACEI group (135 ms +/- 3 vs 150 ms +/- 2, P =.002).
CONCLUSIONS: The use of long-term ACEI therapy facilitated electrical defibrillation in patients with persistent AF. ACEI therapy also reduced SAPD, suggesting amelioration of the arrhythmogenic substrate. Furthermore, we confirmed that SAPD is prolonged in patients with persistent AF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15131537     DOI: 10.1016/j.ahj.2003.07.027

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  18 in total

1.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  Circulation       Date:  2014-03-28       Impact factor: 29.690

2.  Atrial fibrillation and inflammation.

Authors:  Mehmet Ozaydin
Journal:  World J Cardiol       Date:  2010-08-26

Review 3.  The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias.

Authors:  Shahriar Iravanian; Samuel C Dudley
Journal:  Heart Rhythm       Date:  2008-03-04       Impact factor: 6.343

4.  TRPM7-mediated Ca2+ signals confer fibrogenesis in human atrial fibrillation.

Authors:  Jianyang Du; Jia Xie; Zheng Zhang; Hiroto Tsujikawa; Daniel Fusco; David Silverman; Bruce Liang; Lixia Yue
Journal:  Circ Res       Date:  2010-01-14       Impact factor: 17.367

5.  Potential factors that affect electrocardiographic progression of interatrial block.

Authors:  Vignendra Ariyarajah; Mark Kranis; Sirin Apiyasawat; David H Spodick
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-01       Impact factor: 1.468

6.  Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.

Authors:  Rafik R Anis
Journal:  Exp Clin Cardiol       Date:  2009

Review 7.  Hypertension and atrial fibrillation.

Authors:  Orson Go; Clive Rosendorff
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

Review 8.  The past, present and future of renin-angiotensin aldosterone system inhibition.

Authors:  Robert J Mentz; George L Bakris; Bernard Waeber; John J V McMurray; Mihai Gheorghiade; Luis M Ruilope; Aldo P Maggioni; Karl Swedberg; Ileana L Piña; Mona Fiuzat; Christopher M O'Connor; Faiez Zannad; Bertram Pitt
Journal:  Int J Cardiol       Date:  2012-10-31       Impact factor: 4.164

Review 9.  Non-antiarrhythmic medications for atrial fibrillation: from bench to clinical practice.

Authors:  Maya Guglin; Marcos Garcia; Michael J Yarnoz; Anne B Curtis
Journal:  J Interv Card Electrophysiol       Date:  2008-03-04       Impact factor: 1.900

Review 10.  Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation.

Authors:  Gerald V Naccarelli; Frank Peacock
Journal:  Vasc Health Risk Manag       Date:  2009-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.